Author response for "The antiresorptive effect of GIP , but not GLP ‐2, is preserved in patients with hypoparathyroidism– a randomized crossover study"

Skov‐Jeppesen, Kirsa; Hepp, Nicola; Oeke, Jannika; Hansen, Morten Steen; Jafari, Abbas; Svane, Maria S.; Balenga, Nariman; Olson, John A.; Frost, Morten; Kassem, Moustapha; Madsbad, Sten; Jensen, Jens‐Erik Beck; Holst, Jens J.; Hartmann, Bolette

doi:10.1002/jbmr.4308/v2/response1

2021

DOI: 10.1002/jbmr.4308/v2/response1

|View full text |Cite

Author response for "The antiresorptive effect of GIP , but not GLP ‐2, is preserved in patients with hypoparathyroidism– a randomized crossover study"

Kirsa Skov‐Jeppesen¹,

Nicola Hepp²,

Jannika Oeke³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

GIP receptor reduces osteoclast activity and improves osteoblast survival by activating multiple signaling pathways

Hansen

Søe

Christensen³

et al. 2022

Preprint

View full text Add to dashboard Cite

Bone is a dynamic tissue that is remodeled throughout life by bone resorbing osteoclasts and bone forming osteoblasts, to adapt to physiological or mechanical demands. These processes are impaired in osteoporosis, and understanding how bone remodeling is regulated could improve anti-osteoporotic treatments. Clinical investigations show that short-term treatment with glucose-dependent insulinotropic polypeptide (GIP) acutely decreases serum markers of bone resorption and may increase bone formation. However, evidence for direct effects of GIP intracellular signaling and functions in mature human osteoclasts and osteoblasts have not been investigated. We report that the GIP receptor (GIPR) is robustly expressed in mature human osteoclasts. Exposure of osteoclasts to GIP inhibits osteoclastogenesis, delays bone resorption, and increases osteoclast apoptosis by acting upon multiple signaling pathways (cAMP, Src, Akt, calcium, p38) to impair nuclear translocation of nuclear factor of activated T cells 1 (NFATc1) and nuclear factor-κB (NFκB). Human osteoblasts also express GIPR, and GIP improves osteoblast survival via cAMP and Akt-mediated pathways. GIP treatment of co-cultures of osteoclasts and osteoblasts also decreased bone resorption. Antagonizing GIPR with GIP(3-30)NH2 abolished the effects of GIP on osteoclasts and osteoblasts. This study demonstrates that GIP inhibits bone resorption and improves survival of human osteoblasts, which could increase bone mass and strength, supporting clinical investigations of the effect of GIP on bone. Moreover, this study demonstrates that GIPR agonism could be beneficial in the treatment of disorders of bone remodeling, such as osteoporosis.

show abstract

GIP receptor reduces osteoclast activity and improves osteoblast survival by activating multiple signaling pathways

Hansen

Søe

Christensen³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Author response for "The antiresorptive effect of GIP , but not GLP ‐2, is preserved in patients with hypoparathyroidism– a randomized crossover study"

Cited by 1 publication

References 0 publications

GIP receptor reduces osteoclast activity and improves osteoblast survival by activating multiple signaling pathways

GIP receptor reduces osteoclast activity and improves osteoblast survival by activating multiple signaling pathways

Contact Info

Product

Resources

About